GSK's first-quarter sales slide

Share this article:
GSK and nonprofit shrink Big Data down to size
GSK's Q1 sales slide

GlaxoSmithKline's first quarter fizzled, missing sales estimates by 3%. Overall sales fell 10% compared to the same period last year, to $9.5 billion.

US pharmaceutical sales slid 15% compared to the same period a year earlier. GSK attributed the gap to wholesaler destocking, and tight competition for asthma medication Advair. Respiratory sales were down 11%, and volume contracted 13% compared to the previous quarter.

Advair sales fell 30% compared to the same period last year. The company noted that “uptake of recently launched [COPD medication] Breo has also been slower than anticipated.” GSK said payers were slow to cover the new drug, but it expects recent negotiations will move uptake forward. The company also announced that it will seek to expand Breo's indication to include asthma, and called out that it has six late-stage respiratory programs.

As noted by the Wall Street Journal, GSK's respiratory unit drives profit, and pressure on this unit will only increase once Novartis owns GSK's oncology business.

The US was the only region where business contracted during the quarter, but the company corruption allegations in China ate into the Emerging Markets business. China sales fell 20% compared to the same period last year, though overall EM sales grew 3% during the quarter.

Consumer sales—which will become part of the GSK-Novartis joint venture—were flat.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in News

Email Newsletters

More in News

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.